// App-Quantinova.ai

4053 : Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)

Researchers

Presenter

  • Andrzej Jakubowiak

Principal Investigators

  • Nizar J. Bahlis

  • David S. Siegel

  • Christine I. Chen

  • Min Chen

  • Mohamed Zaki

  • Gail Larkins

  • Kenneth C. Anderson

Medical Centers

  • University of Calgary, Southern Alberta Cancer Research Institute, Calgary, AB, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Subarachnoid hemorrhage

  • Peripheral neuropathy

  • Deep vein thrombosis

  • Thrombocytopenia

  • Neutropenia

  • Venous thrombosis

  • Dyspnea

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Bortezomib

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved